2seventy bio is a cell and gene therapy company focused on the research, development, and commercialization of treatments for cancer. Co. develops chimeric antigen receptor (CAR) T cell therapy for multiple myeloma. Co. is developing various clinical programs, including DARIC33, for the treatment of pediatric patients with relapsed and refractory acute myeloid leukemia and bbT369, for the treatment of patients with B-cell non-Hodgkins lymphoma, as well as preclinical programs, including bbT4015, a CAR T cell therapy targeting MUC16. Additionally, Co. is developing ABECMA for the treatment of adults with multiple myeloma who have received at least four prior lines of therapy. The TSVT average annual return since 2021 is shown above.
The Average Annual Return on the TSVT average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether TSVT average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the TSVT average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|